-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Myelofibrosis: When to Refer for Allogeneic Transplantation

Program: Education Program
Session: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
Monday, December 7, 2020, 8:55 AM-9:00 AM

Olatoyosi Odenike, MD

University of Chicago, Chicago, IL

Disclosures: Odenike: Impact Biomedicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astex Pharmaceuticals, NS Pharma, Gilead Sciences, Janssen Oncology, Oncotherapy, Agios, CTI/Baxalta, Aprea: Other: Institutional research funding; Astra Zeneca: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Other: Institutional research funding.

See more of: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
See more of: Education Program
<< Previous Presentation | Next Presentation